What have we learned about vaginal infections and preterm birth?

[1]  Brett A. Collins,et al.  Failure of metronidazole to prevent preterm delivery among pregnant women with asymptomatic Trichomonas vaginalis infection. , 2001, The New England journal of medicine.

[2]  J. Paavonen,et al.  Vaginal Clindamycin in Preventing Preterm Birth and Peripartal Infections in Asymptomatic Women With Bacterial Vaginosis: A Randomized, Controlled Trial , 2001, Obstetrics and gynecology.

[3]  J. Peipert,et al.  Screening for bacterial vaginosis in pregnancy. , 2001, American journal of preventive medicine.

[4]  M. Dombrowski,et al.  The Preterm Prediction Study: association between cervical interleukin 6 concentration and spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 2001, American journal of obstetrics and gynecology.

[5]  J. Paavonen,et al.  A randomised controlled trial of vaginal clindamycin for early pregnancy bacterial vaginosis , 2000, BJOG : an international journal of obstetrics and gynaecology.

[6]  G. Thurnau,et al.  The Preterm Prediction Study: association of second-trimester genitourinary chlamydia infection with subsequent spontaneous preterm birth. , 2000, American journal of obstetrics and gynecology.

[7]  B. Sibai,et al.  Vaginal fetal fibronectin measurements from 8 to 22 weeks' gestation and subsequent spontaneous preterm birth. , 2000, American journal of obstetrics and gynecology.

[8]  M. Dombrowski,et al.  The preterm prediction study: granulocyte colony-stimulating factor and spontaneous preterm birth. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 2000, American journal of obstetrics and gynecology.

[9]  Ichael,et al.  Metronidazole to prevent preterm delivery in pregnant women with asymptomatic bacterial vaginosis. National Institute of Child Health and Human Development Network of Maternal-Fetal Medicine Units. , 2000, The New England journal of medicine.

[10]  A. Helwig,et al.  Bacterial vaginosis in pregnancy and the risk of prematurity: a meta-analysis. , 1999, The Journal of family practice.

[11]  H. Bruinse,et al.  Prophylactic administration of clindamycin 2 % vaginal cream to reduce the incidence of spontaneous preterm birth in women with an increased recurrence risk: a randomised placebo‐controlled double‐blind trial , 1999, British journal of obstetrics and gynaecology.

[12]  H. McClean.  Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora , 1998, British journal of obstetrics and gynaecology.

[13]  P. McDonald,et al.  Impact of metronidazole therapy on preterm birth in women with bacterial vaginosis flora (Gardnerella vaginalis): a randomised, placebo controlled trial , 1997, British journal of obstetrics and gynaecology.

[14]  R. Steele.  Reduced Incidence of Preterm Delivery with Metronidazole and Erythromycin in Women with Bacterial Vaginosis , 1996, Clinical pediatrics.

[15]  E. Thom,et al.  The Preterm Prediction Study: Fetal Fibronectin, Bacterial Vaginosis, and Peripartum Infection , 1996, Obstetrics and gynecology.

[16]  S. Hillier,et al.  Intravaginal clindamycin treatment for bacterial vaginosis: effects on preterm delivery and low birth weight. , 1995, American journal of obstetrics and gynecology.

[17]  E. Thom,et al.  The preterm prediction study: significance of vaginal infections. National Institute of Child Health and Human Development Maternal-Fetal Medicine Units Network. , 1995, American journal of obstetrics and gynecology.

[18]  J. Carey,et al.  Outcome of the Vaginal Infections and Prematurity Study: results of a clinical trial of erythromycin among pregnant women colonized with group B streptococci. , 1995, American Journal of Obstetrics and Gynecology.

[19]  N. Padian,et al.  Plasma Cell Endometritis in Women With Symptomatic Bacterial Vaginosis , 1995, Obstetrics and gynecology.

[20]  John A. Albritton,et al.  Effect of metronidazole in patients with preterm birth in preceding pregnancy and bacterial vaginosis: a placebo-controlled, double-blind study. , 1994, American journal of obstetrics and gynecology.

[21]  J. French,et al.  Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. , 1994, American journal of obstetrics and gynecology.

[22]  W. Poole,et al.  A randomized placebo‐controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery , 1992 .

[23]  N. Kiviat,et al.  Microbiologic causes and neonatal outcomes associated with chorioamnion infection. , 1991, American journal of obstetrics and gynecology.

[24]  W. Poole,et al.  A randomized placebo-controlled trial of erythromycin for the treatment of Ureaplasma urealyticum to prevent premature delivery , 1991 .

[25]  N. Kiviat,et al.  A case‐control study of chorioamnionic infection and histologic chorioamnionitis in prematurity , 1989, The New England journal of medicine.

[26]  J. Feldman,et al.  Risk factors for prematurity and premature rupture of membranes: a prospective study of the vaginal flora in pregnancy. , 1984, American journal of obstetrics and gynecology.

[27]  P. Hardy,et al.  PREVALENCE OF SIX SEXUALLY TRANSMITTED DISEASE AGENTS AMONG PREGNANT INNER-CITY ADOLESCENTS AND PREGNANCY OUTCOME , 1984, The Lancet.

[28]  C. Doré,et al.  Effect of intravaginal clindamycin cream on pregnancy outcome and on abnormal vaginal microbial flora of pregnant women. , 2000, Infectious diseases in obstetrics and gynecology.

[29]  R. Gibbs,et al.  Double-Blind Placebo-Controlled Treatment Trial of Chlamydia trachomatis Endocervical Infections in Pregnant Women , 1997, Infectious diseases in obstetrics and gynecology.